Thromb Haemost 2003; 89(04): 599-600
DOI: 10.1055/s-0037-1613565
Editorial
Schattauer GmbH

Theme issue: Fibrinogen and fibrin – structure, function, interactions and clinical applications

Carl-Erik Dempfle
1   University Hospital, I. Department of Medicine, Mannheim, Germany
,
Michael W. Mosesson
2   The Blood Research Institute, Milwaukee, Wisconsin, U.S.A.
› Author Affiliations
Further Information

Publication History

Publication Date:
07 December 2017 (online)

 

 
  • References

  • 1 Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003; 89: 409-19.
  • 2 Shainoff JR, DiBello PM. The circulatory half-lives of alpha-profibrin and alpha-fibrin monomer, and comparisons with other fibrin(ogen) derivatives. Thromb Haemost 2003; 89: 48-52.
  • 3 Shainoff JR, DiBello PM. Fibrin precursors, intermediaries for hemostasis in the clot war. Thromb Res 2002; 105: 3-13.
  • 4 Meyer M, Franke K, Richter W. et al. New molecular defects in the Ysubdomain of fib-rinogen D-domain in four cases of (hypo) dysfibrinogenemia. Thromb Haemost 2003; 89: 637-46.
  • 5 Amiconi G, Caracciolo G, De Spirito M. et al. Protofibrils within fibrin fibres are packed together in a regular tetragonal array. Thromb Haemost 2003; 89: 632-6.
  • 6 Ferri F, Greco M, Arcovito G, De Spirito M, Rocco M. Structure of fibrin gels studied by elastic light scattering techniques: dependence of fractal dimension, gel crossover length, fiber diameter, and fiber density on monomer concentration. Phys Rev E Stat Nonlin Soft Matter Phys 2002; 66 (01) 011913.
  • 7 Ramstrom S, Ranby M, Lindahl TL. The role of platelets in blood coagulation - effects of platelet agonists and GPIIb/IIIa inhibitors studied by free oscillation rheometry. Thromb Res 2002; 105: 165-72.
  • 8 Meh DA, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid sequence in fibrin responsible for high affinity thrombin binding. Thromb Haemost 2001; 85: 470-4.
  • 9 de Bosch NB, Mosesson MW, Ruiz-Saez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost 2002; 88: 253-8.
  • 10 Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89: 9-12.
  • 11 Lovely RS, Falls LA, Al-Mondhiry HA. et al. Association of γA/γ’ fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88: 26-31.
  • 12 Koenig W. Fibrin(ogen) in cardiovascular disease. Thromb Haemost 2003; 89.
  • 13 Koenig W, Rothenbacher D, Hoffmeister A, Griesshammer M, Brenner H. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol 2001; 21: 1701-5.
  • 14 Pfaffenberger S, Devcic-Kuhar B, El-Rabadi K. et al. 2MHz ultrasound enhances t-PA-mediated thrombolysis: comparison of continuous versus pulsed ultrasound and standing versus travelling acoustic waves. Thromb Haemost 2003; 89: 583-9.
  • 15 Ruppert C, Markart P, Schmidt R. et al. Chemical crosslinking of urokinase to pulmonary surfactant protein B for targeting alveolar fibrin. Thromb Haemost 2003; 89: 53-64.
  • 16 Wong C, Inman E, Spaethe R, Helgerson S. Fibrin-based biomaterials to deliver human growth factors. Thromb Haemost 2003; 89: 573-82.
  • 17 Taylor Jr. FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-30.